Finance

Shares within the sport: Bombardier Inc. – Yahoo Canada Finance

GlobeNewswire

Polycystic Ovarian Syndrome (PCOS) Treatment Market Expected to Reach $ 4.6 Billion By 2027

Project Details: – StrategyR – A trademark of Global Industry Analysts, Inc. – Project Issue: 9. – Influencer Pool: 1173. – MarketGlass ™ Platform – Our influencer-driven interactive research platform is based on unique perspectives from participating executives from featured companies York, December 31st March 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces Release of Global Polycystic Ovary Syndrome (PCOS) Treatment Industry Report – https://www.reportlinker.com/p06042932/?utm_source=GNW In MarketGlass ™ is not just a global platform for information exchange, but also a powerful knowledge center that delivers dynamic project-oriented market information. Client companies have full insider access to the project data stack. – Interactive peer-to-peer and enterprise-to-enterprise brainstorming as well as the exchange of market information are facilitated by a robust, secure and validated process. The process is based on uniquely qualified project-specific and geographically focused executives who oversee business development, marketing and sales. Trends & Factors – Identify and validate local trends and factors that determine any competitive market. These factors include price variances, market histories, the impact and recovery of Covid-19, locally active leading brands, and other short to medium term effects on the region such as: B. Realignment of the supply chain. Mobile Access & App – Our mobile version of the report can be accessed through our mobile app or directly for a full mobile experience. Free updates – for one year. At least one update within 12 months is normal and there is always when the market dynamics change significantly. Special Updates and Team Collaboration – Customers can create a bespoke version of our report with colleagues on our MarketGlass ™ platform, which enables multi-dimensional data simulation. Knowledge Center – Customers have full access to project data they support or acquire, including statistics on primary research assignments, companies, and executives. Summary: – The global polycystic ovarian syndrome (PCOS) treatment market is projected to reach $ 4.6 billion by 2027. – Amid the COVID-19 crisis, the global polycystic ovarian syndrome (PCOS) treatment market is estimated to be US $ 3.6 billion in 2020 and will reach a revised size of US $ 4.6 billion by 2027 and during the analysis period Grow with a CAGR of 3.5% in 2020-2027. Oral contraceptives, one of the segments analyzed in the report, are expected to have a CAGR of 5% and reach $ 1.2 billion by the end of the analysis period. After an early analysis of the business impact of the pandemic and its triggered economic crisis, growth in the anti-androgen segment will be adjusted to a revised CAGR of 3.7% for the next 7 year period. – The US market is valued at $ 981.1 million while China is expected to grow 6.4% CAGR. – The US Polycystic Ovarian Syndrome (PCOS) Treatment Market is estimated at $ 981.1 million in 2020. China, the world's second largest economy, is expected to reach a forecast market size of $ 983.7 million by 2027, corresponding to a CAGR of 6.6% over the analysis period 2020 to 2027. Other notable geographic markets include Japan and Canada, which are forecast to grow 1% and 2.6% respectively over the 2020-2027 period. Within Europe, growth of around 1.7% CAGR is forecast for Germany. – Insulin Sensitizers segment with a CAGR of 3.1% – In the global Insulin Sensitizers segment, the US, Canada, Japan, China and Europe will increase the CAGR estimated for this segment by 2.6%. These regional markets, with a combined market size of $ 924 million in 2020, are projected to reach a projected size of $ 1.1 billion by the end of the analysis period. China will continue to be one of the fastest growing in this cluster of regional markets. Led by countries like Australia, India and South Korea, the Asia-Pacific market is projected to reach $ 646 million by 2027, while Latin America is expected to expand at an annual growth rate of 3.9% over the analysis period. – Selected Competitors (42 recommended total) – Addex TherapeuticsAstraZeneca PLCBristol-Myers Squibb CompanyCrinetics Pharmaceuticals, Inc.Ferring Pharmaceuticals, Inc.JSC BIOCADMerck KgaATeva Pharmaceutical Industries Ltd. Read the full report: https://www.reportlinker.com/p06042932/? utm_source = GNW I. METHODOLOGY II. SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World market developments Effects of Covid-19 and an emerging global recession 2. FOCUS ON SELECTED PLAYERS 3. MARKET TRENDS AND DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: Current and future analysis of the World For Polycystic Ovaries Syndrome (PCOS) Treatment By Geographical Areas – US, Canada, Japan, China, Europe, Asia Pacific, Latin America, Middle East, and Africa Markets – Independent Analysis of Annual Revenue, Million Dollar USD for 2020 to 2027 and% CAGR Table 2: World Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Geographic Area – US, Canada, Japan, China, Europe, Asia Pacific, Latin America Markets , Middle East and Africa – Independent analysis of annual sales in USD million for years 2012 to 2019 and% CAGR Table 3: Worldwide 1st 5 Year Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Geographic Area – Percentage Breakdown of Value Sales for US, Canada, Japan, China, Europe, Asia Pacific markets for FIC, Latin America, Middle East and Africa for the years 2012, 2020 and 2027 Table 4: Worldwide Current and Future Analysis for Oral Contraceptives by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Central America East and Africa Markets – Independent Analysis of Annual Sales in Million . USD for 2020 to 2027 and% CAGR Table 5: World Historical Overview of Oral Contraceptives by Geographic Region – US, Canada, Japan, China, Europe, Asia-Pacific, Latin Markets in America, Middle East and Africa – Independent Analysis of annual sales in USD million for the years 2012 to 2019 and% CAGR Table 6: Worldwide 15-year perspective for oral contraceptives by geographic region – percentages Value Sales Breakdown for the United States, Canada, Japan, China, Europe, Asia Pacific, Latin America, the Middle East, and Africa for 2012, 2020, and 2027 Table 7: Worldwide Current and Future Analysis for Antiandrogens by Geographic Area – United States, Canada , Japan, China, Europe, Asia-Pacific, Latin America a, Middle East and Africa markets – Independent analysis of annual sales in USD million for the years 2020 to 2027 and% CAGR Table 8: World historical overview of antiandrogens by geographic region – United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Revenue in Million US Dollars for the Years 2012 to 2019 and% CAGR Table 9: Worldwide 15-Year Anti-Androgen Perspective by Geographic Region – Percentage Breakdown of Value Sales for the US, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East and Africa for 2012, 2020 and 2027 Table 10: Current and Future Analysis of the World for Insulin Sensitizing Drugs by Geographic Region – United States, Canada, Japan, China, Markets in Europe, Asia Pacific, Latin America, the Middle East and Africa – Independent Analysis of the Annual sales in million US dollars for the years 2020 to 2027 and% CAGR Table 11: World historical overview of insulin sensitizing agents by geographic region – USA, Canada, J. Markets in Apan, China, Europe, Asia-Pacific, Latin America, in the Middle East and Africa – Independent Analysis of Annual Revenue in USD Million for the Years 2012 to 2019 and% CAGR Table 12: Worldwide 15-Year Perspective for Insulin Sensitizing Agents by Geographic Region – Percentage Breakdown of Value Sales for the US, Canada, Japan, China, Europe, Asia Pacific, Latin America, the Middle East and Africa for 2012, 2020 and 2027 Tabe lle 13: Worldwide Current and Future Analysis for Antidepressants by Geographic Region – Markets in the United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East and Africa – Independent analysis of annual sales in millions USD for 2020-2027, and% CAGR Table 14: World Historic Review for Antidepressants by Geographic Region – US, Canada, Japan, China, Europe, Asia Pacific, Latin America, Middle East, and Africa markets – Independent analysis of annual sales in USD million for the years 2012 to 2019 and% CAGR Table 15: World 15 year perspective for antid epressants by geographic region – Percentage breakdown of value sales for the USA, Canada, Japan, China, Europe, Asia – Pacific, Latin America, the Middle East and Africa for the years 2012, 2020 and 2027 Table 16: Current and future world analysis for anti-obesity pathogens by geographic region en – United States, Canada, Japan, China, Europe, Asia Pacific, Latin America, Middle East and Africa – Independent Analysis of Annual Revenue in USD Million for the Years 2020 to 2027 and% CAGR Table 17: World Historical Overview of Obesity Remedies By geographic region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa – Independent analysis of annual sales in USD million for the years 2012 to 2019 and% CAGR Table 18: Worldwide 15-year Obesity Remedies Perspective by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia Pacific, Latin America, Middle East and Africa for 2012, 2020 & 2027 Table 19: World Current & Fut Ovarian Wedge Resection Analysis by Geographic Region – USA, Canada, Japan, China, Europe, Asia Pacific, Latin America, Middle East and Africa – Independent analysis of annual sales in USD million for 2020 to 2027 and% CAGR Table 20: World Historical Overview of Ovarian Wedge Resection by Geographic Region – Markets in the US, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East and Africa – Independent analysis of annual sales in USD million for the years 2012 to 2012 2019 and% CAGR Table 21: Worldwide 15-year perspective for ovarian wedge resection by geographical region – percentage breakdown of value sales for the USA, Canada, Japan, China, Europe, the Asia-Pacific region Area, Latin America, the Middle East and Africa for 2012, 2020 & 2027 Table 22: Worldwide current and future analysis for laparoscopic ovarian drilling by geographic region – markets in the USA, Canada, Japan, China, Europe, Asia-Pacific , Latin America, Middle East and Africa – Independent Analysis of Annual Revenue in Million US Dollars for the Years 2020 to 2027 and% CAGR Table 23: World Historical Review of Laparoscopic Ovarian Drills by Geographic Region – US, Canada, Japan, China, Europe, Asia Pacific, Latin America, Middle East and Africa Markets – Independent Analysis of Annual Revenue in USD Million for 2012 by 2019 and% CAGR Table 24: Worldwide 15-Year Perspective for Laparoscopic Ovarian Drills by Geographic Region – Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for 2012 , 2020 and 2027 III. UNITED STATES MARKET ANALYSIS Table 25: Current and Future US Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Drugs – Independent Analysis of Annual Sales in USD Millions for the Years 2020 through 2027 and% CAGR Table 26: U.S. Historical Review of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Drugs Markets – Independent Analysis of Annual Sales in USD Millions for Years 2012 to 2019 and% CAGR Table 27: USA 15-year perspective for the treatment of polycystic ovarian syndrome (PCOS) by drug class – percentage breakdown of value sales for oral contraceptives, antiandrogens, insulin sensitizers, antidepressants and anti-obesity agents for 2012, 2020 and 2027 Table 28: Current and Future US Analysis for Surgical Treatment of Polycystic Ovarian Syndrome (PCOS) Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Revenue in USD Millions for 2020 to 2027 and % CAGR Table 29: U.S. Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Revenue in Million US Dollars for Years 2012-2019 and% CAGR Table 30: 15 Year – U.S. Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Surgery Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012, 2020 and 2027 CANADA Table 31: Canada Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS ) according to active ingredient classes – oral contraceptives, antiandrogens, insulin sensitizers, antidepressants and anti-obesity agents – independent analysis of annual sales in USD million for the years 2020 to 2027 and% CAGR Table 32: Canada Historic Review for Polyc treatment of ystic ovarian syndrome (PCOS) by drug class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Drugs Markets – Independent Analysis of Annual Sales in USD Millions for Years 2012-2019 and% CAGR Table 33: Canada 15-Year Perspective for Polycystic Ovarian Syndrome Treatment ( PCOS) by drug class – percentage breakdown of value sales for oral contraceptives, antiandrogens, insulin sensitizers, antidepressants and anti-obesity agents for 2012, 2020 and 2027 Table 34: Canada Current and future analysis of polycystic ovarian syndrome (PCOS) treatment by surgical style p – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Revenue in USD Million for the Years 2020 to 2027 and% CAGR Table 35: Canada Historic Review for Polycystic Treatment of Ovarian Syndrome (PCOS) by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Revenue in millions of US dollars for the years 2012 to 2019 and% CAGR Table 36: Canada's 15-Year Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Percentage Breakdown of Revenue for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012 , 2020 & 2027 JAPAN Table 37: Japan Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Agents – Independent Analysis of Annual Sales in USD Million for 2020 to 2027 and% CAGR Table 38: Japanese Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Agents – Independent Analysis of Annual Sales in Millions USD for 2012 to 2019 and% CAGR Table 39: Japan 15-Year Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Agents for 2012, 2020 and 2027 Table 40: Japan Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Sales in Millions of US Dollars for Years 2020 to 2027 and% CAGR Table e 41: Japanese Historical Review of Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovary Drilling Markets – Independent Analysis of Annual Revenue in USD Million for 2012 to 2019 and% CAGR Table 42: Japanese 15 Year Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Percentage Breakdown of Value for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012, 2020 and 2027 CHINA Table 43: China's Current and Future Analysis for Polycystic Ovarian Syndrome (PCO) S) Treatment According to Drug Classes – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Drugs – Independent Analysis of Annual Sales in USD Million for the Years 2020 to 2027 and% CAGR Table 44: China Historic Review for Polycystic Treatment of Ovarian Syndrome (PCOS) by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Agents Markets – Independent Analysis of Annual Revenue in Million USD for Years 2012 to 2019 and% CAGR Table 45: China 15-Year Outlook for Polycystic Ovarian Syndrome (PCOS) Treatment According to Drug Classes – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Agents for 2012, 2020, and 2027 Table 46: China Current & Future Analysis for Polycystic Ovarian Syndrome (PCOS) Treatment by Type of Surgery – Ovarian Wedge Resection Laparoscopic Ovarian Drilling – Independent Analysis of Annual Sales in USD Million for 2020 to 2027 and% CAGR Table 47: China Historic Review of Polycystic Ovarian Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – U Independent analysis of annual sales in USD million for the years 2012 to 2019 and% CAGR Table 48: China's 15-Year Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012, 2020 and 2027 EUROPE Table 49: Current and Future Analysis of Europe for Polycystic Ovarian Syndrome (PCOS) Treatment by Geographic Area – Markets in France, Germany, Italy, United Kingdom, Spain, Russia and the rest of Europe – Independent analysis of the Annual sales in USD million for the years 2020 to 2020 2027 and% CAGR Table 50: Europe Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Geographic Area – France, Germany, Italy, Great Britain, Spain, Russia and the rest of Europe Mar . kets – Independent analysis of annual sales in USD million for the J age 2012 to 2019 and% CAGR Table 51: Europe 15-year outlook for Polycystic Ovarian Syndrome (PCOS) treatment by geographic region – Percentage breakdown of value sales for France, Germany, Italy, Great Britain, Spain, Russia and the rest of Europe Markets for 2012, 2020 and 2027 Table 52: Current and Future Analysis of Europe for Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants and Anti-Obesity Drugs – Independent Analysis of Annual Sales in Million US Dollars for 2020-2027 and% CAGR Table 53: Europe Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants and Obesity Agents Markets – Independent Analysis of Annual Revenue in million en US dollars for the years 2012 to 2019 and% CAGR Table 54: Europe 15-year perspective for polycystic diseases Treatment of ovarian syndrome (PCOS) by drug class – percentage breakdown of value sales for oral contraceptives, antiandrogens, insulin sensitizers, antidepressants and Obesity Means for 2012, 2020 and 2027 Table 55: Current and Future Analysis of Europe for Polycystic Disease Treatment of Ovarian Syndrome (PCOS) by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Revenue in Million USD for the Years 2020 to 2027 and% CAGR Table 56: Europe Historic Review for Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Revenue in USD Million for the Years 2012 to 2019 and% CAGR Table 57: Europe-15- Year perspective for the treatment Polycystic Ovarian Syndrome (PCOS) Analysis by Type of Surgery – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012, 2020 and 2027 FRANCE Table 58: France C. Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral contraceptives, antiandrogens, insulin sensitizers, antidepressants and anti-obesity agents – Independent analysis of annual sales in USD million for the years 2020 to 2027 and% CAGR Table 59: France Historical Overview of Polycystic Ovarian Syndrome (PCOS) treatment by drug class – Oral Contraceptive, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Drugs Markets – Independent Analysis of Annual Revenue in Million USD for Years 2012 to 2012 2019 and% CAGR Table 60: France 15 Year Perspective for Polycystic Treatment Ovarian Syndrome (PCOS) by Drug Class – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Agents for 2012, 2020 & 2027 Table 61: France Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment By Operation Type – Ovarian Wedge Resection and L. Aparoscopic Ovarian Drilling – Independent Analysis of Annual Revenue in Millions of US Dollars for 2020-2027 and% CAGR Table 62: France Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent analysis of annual sales in USD million for the years 2012 to 2019 and% CAGR Table 63: France 15-year perspective for the treatment of Polycystic Ovarian Syndrome (PCOS) by type of operation – Percentage breakdown of the value sales for d he ovarian wedge resection and laparoscopic ovarian drilling for the years 2012, 2020 & 2027 GERMANY Table 64: Germany Current and future analysis of the treatment of polycystic ovarian syndrome (PCOS) by drug class – oral contraceptives, antiandrogens, insulin sensitizing agents, antidepressants and agents against obesity – independent analysis of annual sales in USD millions for the years 2020 to 2027 and% CAGR Table 65: Germany Historical Review of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Drugs Markets – Independent Analysis of annual sales in USD million for the years 2012 to 2019 and% CAGR Table 66: Germany 15-year perspective for polycystic diseases Treatment of ovarian syndrome (PCOS) by drug class – percentage breakdown of value sales for oral contraceptives a, antiandrogens, insulin sensitizers, antidepressants and anti-obesity agents for 2012, 2020 and 2027 Table 67: Germany Current and future analysis for polycystic diseases Treatment of ovarian syndrome (PCOS) by type of operation – Ovarian wedge resection and laparoscopic ovarian drilling – Independent analysis of annual turnover in Million USD for 2020 to 2027 and% CAGR Table 68: Germany Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Revenue in Million US Dollars for Years 2012 to 2019 and % CAGR Table 69: Germany 15 Year Perspective for Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012, 2020 and 2027 ITALY Table 70: Italy Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Agents – Independent Analysis of Annual Revenue in Millions of US Dollars for the Years 2020 to 2027 and% CAGR Table 71: Italy Historical Overview of Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Anti-Obesity Drugs Markets – Independent Analysis of Annual Sales in USD Millions for Years 2012 to 2019 and% CAGR Table 72: Italy 15-year perspective for the treatment of polycystic ovarian syndrome (PCOS) by drug class – percentage value breakdown Sales of oral contraceptives, antiandrogens, insulin sensitizing agents, antidepressants and agents against obesity for years 2 012, 2020 and 2027 Table 73: Italy Current and Future Analysis of Polycystic Ovarian Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Sales in Million US Dollars for Years 2020 to 2027 and% CAGR Table 74: Italian Historical Review of Polycystic Ovarian Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Revenue in USD Million for Years 2012 to 2019 and% CAGR Table 75: Italy 15 Year Perspective for Treatment of Polycystic Ovarian Syndrome (PCOS) by Operation Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for 2012, 2020 and 2027 UNITED KINGDOM Table 76: Current and Future UK Analysis of Polycystic Ovarian Syndrome Treatment roms (PCOS) by D. Carpet Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Agents – Independent Analysis of Annual Sales in Millions of US Dollars for 2020-2027 and% CAGR Table 77: UK Historic Review for the Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Agents Markets – Independent Analysis of Annual Revenue in USD Million for 2012-2019 and% CAGR Table 78: 15 Year Perspective for UK Polycystic Ovarian Syndrome (PCOS) Treatment by Drug Class – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogens, Insulin Sensitizers, Antidepressants, and Obesity Agents for 2012, 2020 and 2027 Table 79: UK Current & Future Analysis for Polycystic Treatment Ovarian syndrome roms (PCOS) by Operation Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Revenue in USD Million for t Years 2020 to 2027 and% CAGR Table 80: United Kingdom Historical Review of Polycystic Ovarian Syndrome (PCOS) Treatment by Operation Type – Ovarian Wedge Resection und laparoskopische Eierstockbohrmärkte – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2012 bis 2019 und 2019 % CAGR Tabelle 81: 15-Jahres-Perspektive des Vereinigten Königreichs für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Operationstyp – prozentuale Aufschlüsselung der Wertverkäufe für die Ovarialkeilresektion und die laparoskopische Ovarialbohrung für die Jahre 2012, 2020 und 2027 SPANIEN Tabelle 82: Spanien Aktuell & Zukünftige Analyse für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklassen – Orale Kontrazeptiva, Antiandrogene, insulinsensibilisierende Mittel, Antidepressiva u nd Mittel gegen Fettleibigkeit – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2020 bis 2027 und% CAGR-Tabelle 83: Spain Historic Review für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklassen – orale Kontrazeptiva, Antiandrogen, insulinsensibilisierende Mittel, Antidepressa Märkte für NTS- und Anti-Adipositas-Wirkstoffe – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2012 bis 2019 und% CAGR Tabelle 84: Spanien 15-Jahres-Perspektive für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklasse – prozentuale Aufschlüsselung des Umsatzes für orale Kontrazeptiva, Antiandrogene, insulinsensibilisierende Mittel, Antidepressiva und Mittel gegen Fettleibigkeit für die Jahre 2012, 2020 und 2027 Tabelle 85: Spanien Aktuelle und zukünftige Analyse der Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Operationstyp – Ovarialkeilresektion und Laparoskopie Eierstockbohrung – Unabhängige Analyse des Jahresum satzes in Mio. USD für die Jahre 2020 bis 2027 und% CAGR Tabelle 86: Spanien Historischer Überblick über die Behandlung des polyzystischen Eierstock-Syndroms (PCOS) nach Operationstyp – Eierstockkeilresektion und laparoskopische Eierstockbohrmärkte – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2012 bis 2019 und% CAGR Tabelle 87: Spanien 15-Jahres-Perspektive für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) Ent nach Operationstyp – Prozentuale Aufschlüsselung der Wertverkäufe für die Ovarialkeilresektion und das laparoskopische Ovarialbohren für die Jahre 2012, 2020 und 2027 RUSSLAND Tabelle 88: Russland Aktuelle und zukünftige Analyse der Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklasse – Orale Kontrazeptiva, Antiandrogen, insulinsensibilisierende Mittel, Antidepressiva und Mittel gegen Fettleibigkeit – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2020 bis 2027 und% CAGR Tabelle 89: Russland Historischer Über blick über die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklassen – Markt für orale Kontrazeptiva, Antiandrogene, insulinsensibilisierende Mittel, Antidepressiva und Mittel gegen Fettleibigkeit – Unabhängige Analyse des Jahresumsatzes in Millionen US-Dollar für die Jahre 2012 bis 2019 und% CAGR Tabelle 90: Russland 15-Jahres-Perspektive für das polyzystische Ovarialsyndrom (PCOS) Behandlung nach Wirkstoffklasse – Prozentuale Aufschlüsselung der Wertverkäufe für orale Kontrazeptiva, Antiandrogene, insulinsensibilisierende Mittel, Antidepressiva und Anti-Adipositas Wirkstoffe für die Jahre 2012, 2020 und 2027 Tabelle 91: Russland Aktuelle und zukünftige Analyse der Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Operationstyp – Ovarialkeilresektion und laparoskopische Ovarialbohrung – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2020 bis 2027 und% CAGR Tabelle 92: Russland Historischer Überblick über die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Operationstyp – Eierstockkeilresektion und laparoskopische Eierstockbohrmärkte – Unabhängige Analyse des Jahresumsatzes in Mio. USD für die Jahre 2012 bis 2019 und% CAGR-Tabelle 93: Russland 15-Jahres-Perspektive für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Operationstyp – prozentuale Aufschlüsselung des Wertumsatzes für die Ovarialkeilresektion und das laparoskopische Ovarialbohren für die Jahre 2012, 2020 und 2027 REST OF EUROPE Tabelle 94: Restliches Europa aktuell & Zukünftige Analyse für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklassen – orale Kontrazeptiva, Antiandrogen, insulinsensibilisierende Mittel, Antidepressiva und Mittel gegen Fettleibigkeit – Unabhängige Analyse des Jahresumsatzes in Millionen US-Dollar für die Jahre 2020 bis 2027 und% CAGR Tabelle 95: Restliche europäische historische Übersicht über die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Wirkstoffklasse – Orale Kontraze ptiva, Antiandrogen, Insulin – Märkte für Sensibilisierungsmittel, Antidepressiva und Mittel gegen Fettleibigkeit – Unabhängige Analyse des Jahresumsatzes in Millionen US-Dollar für die Jahre 2012 bis 2019 und% CAGR Tabelle 96: 15-Jahres-Perspektive für die Behandlung des polyzystischen Ovarialsyndroms (PCOS) nach Arzneimittelklassen – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027 Table 97: Rest of Europe Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of Europe Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Sales in US $ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of Europe 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 100: Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region – Australia, India, South Korea and Rest of Asia-Pacific Markets – Independent Analysis of Annual Sales in US$ Mill ion for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Geographic Region – Percentage Breakdown of Value Sales for A ustralia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment b y Drug Class – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027 Table 1 06: Asia-Pacific Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Asia-Pacific Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Asia-Pacific 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027 AUSTRALIA Table 109: Australia Curren t & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents – Independ ent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class – Percentage Breakdown of Value Sales for Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents for the Years 2012, 2020 & 2027 Table 112: Australia Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resectio n and Laparoscopic Ovarian Drilling – Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: Australia Historic Review for Polycystic Ovary Synd rome (PCOS) Treatment by Surgery Type – Ovarian Wedge Resection and Laparoscopic Ovarian Drilling Markets – Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: Australia 15-Year Perspective for Polycystic Ovary Syndrome (PCOS) Treatment by Surgery Type – Percentage Breakdown of Value Sales for Ovarian Wedge Resection and Laparoscopic Ovarian Drilling for the Years 2012, 2020 & 2027 INDIA Table 115: India Current & Future Analysis for Polycystic Ovary Syndrome (PCOS) Treatment by Drug Class – Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants and Anti-Obesity Agents – Independent Analysis of Annual Sales in Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www .reportlinker.com/p06042932/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *